PharmAbcine
develops human therapeutic monoclonal antibody... Read morePharmAbcine
develops human therapeutic monoclonal antibody... Read more
News
Oct 15, 2024
centralcharts
Press Release: PharmAbcine : PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
Jul 25, 2024
Korea Biomedical Review
PharmAbcine: PharmAbcine to be delisted from Kosdaq amid financial and operational struggles
Jul 05, 2024
Eyewire News
PharmAbcine: PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMD
Jan 25, 2024
Pharmabiz
PharmAbcine: PharmAbcine begins patient dosing in phase 1a/b trial of PMC309 in combo with Keytruda to treat advanced or metastatic solid tumours
Nov 23, 2023
StreetInsider
Press Release: PharmAbcine : PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
Sep 18, 2023
Korea Biomedical Review
PharmAbcine: PharmAbcine gets Australian nod for p1 clinical trial of Keytruda-combined cancer drug
Jul 26, 2023
PR Newswire
Press Release: PharmAbcine : PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
May 23, 2023
centralcharts
Press Release: PharmAbcine : PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
May 08, 2023
PR Newswire
Press Release: PharmAbcine : PharmAbcine to participate in "BIO International Convention 2023"
Dec 12, 2022
BioSpace
PharmAbcine: PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA (pembrolizumab)